Researchers are actively expanding the use of daratumumab for other CD38+ blood cancers, including acute lymphoblastic leukemia (ALL), natural killer/T-cell lymphoma (NKTCL), and acute myeloid leukemia [6]. Here, CD38 is linked to acute lymphoblastic leukemia.